0 NASDAQ Companies - January 4, 2019Visteon to Present at Deutsche Bank and Wolfe Research Global Auto Industry Conferences in Detroit on Jan. 15VAN BUREN TOWNSHIP, Mich., Jan. 04, 2019 (GLOBE NEWSWIRE) — Visteon Corporation (Nasdaq: VC), a leading global supplier of vehicle […]Read More
0 NYSE Companies - January 4, 2019Armada Hoffler Properties Completes the Anticipated Sale of the New Build-To-Suit Distribution Facility in Richmond, VirginiaVIRGINIA BEACH, Va., Jan. 04, 2019 (GLOBE NEWSWIRE) — Armada Hoffler Properties, Inc. (NYSE: AHH) announced today that it has […]Read More
0 NASDAQ Companies - January 4, 2019T-Mobile US, Inc. to Present at the Citi 2019 Global TMT West Conference in Las Vegas, NevadaBELLEVUE, Wash., Jan. 04, 2019 (GLOBE NEWSWIRE) — Mike Sievert, President & Chief Operating Officer and J. Braxton Carter, Executive […]Read More
0 NASDAQ Companies - January 4, 2019Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications— Initial Clinical Data Expected in First Half of 2020 — CAMBRIDGE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) — Evelo […]Read More
0 NASDAQ Companies - January 4, 2019Zealand Pharma to attend JP Morgan Healthcare Conference and Oddo BHF ForumPress release – No. 2 / 2019 Zealand Pharma to attend JP Morgan Healthcare Conference and Oddo BHF Forum Copenhagen, […]Read More
0 NASDAQ Companies - January 4, 2019Zealand Pharma completes equity investment in strategic partner Beta BionicsPress release – No. 1 / 2019 Zealand Pharma completes equity investment in strategic partner Beta Bionics Zealand Pharma invests […]Read More
0 Canadian Stock Exchange News - January 4, 2019FinCanna Announces Convertible Debenture Financing to Raise CAD $1.5 millionFinCanna Management Team Subscribes to $500,000 of Placement Not for distribution to United States newswire services or for dissemination in […]Read More
0 NASDAQ Companies - January 4, 2019ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period– ASLAN003 is an orally active, potent inhibitor of DHODH that has the potential to be first-in-class in AML– Positive […]Read More
0 TSX Venture News - January 4, 2019Mkango Announces Exercise of OptionsLONDON and VANCOUVER, British Columbia, Jan. 04, 2019 (GLOBE NEWSWIRE) — Mkango Resources Ltd. (AIM/TSX-V: MKA) (the “Company” or “Mkango”) […]Read More
0 NYSE Companies - January 3, 2019Delek US Holdings to Participate in Energy Industry ConferencesBRENTWOOD, Tenn., Jan. 03, 2019 (GLOBE NEWSWIRE) — Delek US Holdings, Inc. (NYSE: DK) today announced that members of management […]Read More